2025-03-26 12:09:35
Latest Post
Gujarat Ambuja Exports Ltd commences commercial production of Greenfield 1200 TPD Maize Processing unit
Wardwizard Promoters take decisive action with Significant Fund Infusion
EaseMyTrip signs MoU with Tourism New Zealand to strengthen travel ties and enhance Indian tourist arrivals
Welspun Corp Limited increases stake in Welspun Specialty Solutions Ltd
Rulka Electricals Secures 21 New Work Orders totaling Rs 12.36 Crore in March 2025
Stock Report
Jagsonpal Pharmaceuticals Ltd posts Rs. 7.47 crore PAT in Q2 FY24
Posted On : 2023-11-04 13:47:06( TIMEZONE : IST )
Jagsonpal Pharmaceuticals Limited has reported Standalone financial results for the period ended September 30, 2023.
Financial Results (Q2 FY2024) - QoQ Comparison
The company has reported total income of Rs. 60.103 crores during the period ended September 30, 2023 as compared to Rs. 62.150 crores during the period ended June 30, 2023.
The company has posted net profit / (loss) of Rs. 7.472 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs. 7.479 crores for the period ended June 30, 2023.
The company has reported EPS of Rs. 2.84 for the period ended September 30, 2023 as compared to Rs. 2.85 for the period ended June 30, 2023.
| Financials | Q2 FY2024 | Q1 FY2024 | % Change |
| Total Income | ₹ 60.103 crs | ₹62.150 crs |  -3.29% |
| Net Profit | ₹7.472 crs | ₹7.479 crs | -0.09% |
| EPS | ₹2.84 | ₹2.85 | -0.35% |
Financial Results (Q2 FY2024) - YoY Comparison
The company has reported total income of Rs. 60.103 crores during the period ended September 30, 2023 as compared to Rs.61.647 crores during the period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.7.472 crores for the period ended September 30, 2023 as against net profit / (loss) of Rs.10.412 crores for the period ended September 30, 2022.
The company has reported EPS of Rs.2.84 for the period ended September 30, 2023 as compared to Rs.3.97 for the period ended September 30, 2022.
| Financials | Q2 FY2024 | Q2 FY2023 | % Change |
| Total Income | ₹ 60.103 crs | ₹61.647 crs | -2.50% |
| Net Profit | ₹7.472 crs | ₹10.412 crs | -28.24% |
| EPS | ₹2.84 | ₹3.97 | -28.46% |
Financial Results (Half Year Ended FY2024) - YoY Comparison
The company has reported total income of Rs.122.253 crores during the 6 Months period ended September 30, 2023 as compared to Rs.122.557 crores during the 6 Months period ended September 30, 2022.
The company has posted net profit / (loss) of Rs.14.951 crores for the 6 Months period ended September 30, 2023 as against net profit / (loss) of Rs.13.334 crores for the 6 Months period ended September 30, 2022.
The company has reported EPS of Rs.5.68 for the 6 Months period ended September 30, 2023 as compared to Rs.5.09 for the 6 Months period ended September 30, 2022.
| Financials | Half Year Ended FY2024 | Half Year Ended FY2023 | % Change |
| Total Income | ₹122.253 crs | ₹122.557 crs | -0.25% |
| Net Profit | ₹14.951 crs | ₹13.334 crs |  12.13% |
| EPS | ₹5.68 | ₹5.09 | 11.59% |
Shares of Jagsonpal Pharmaceuticals Limited was last trading in BSE at Rs. 409.10 as compared to the previous close of Rs. 417.60. The total number of shares traded during the day was 7317 in over 865 trades.
The stock hit an intraday high of Rs. 428.10 and intraday low of 393.45. The net turnover during the day was Rs. 2993204.00.
